The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | ESMO 2018 Congress

Follicular Lymphoma MORE >>

Duvelisib (Copiktra) has been approved by the FDA for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed/refractory follicular lymphoma. Both indications are for the treatment of patients who have received at least 2 prior therapies.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.